Table of contents
View Supplies

Peptide Dosage Chart: Doses for 44 Peptides and 11 Stacks

Compare common research doses for every peptide and stack on this site in one place. Each row shows the dose, how often it's taken, the route, and where the number comes from, with a link to the full guide.

Educational reference only. Most peptides here are not FDA-approved, and a dose on this chart is not a recommendation to use one.

Every row links to a full, sourced dosing guide

By Garret GrantFounder & Lead ResearcherLast reviewed November 2026Prefer us on Google

Peptide Dosage Chart at a Glance

This chart shows the seven peptides people look up most. The full tables below cover every peptide and stack, grouped by goal.

Peptide dosage chart: semaglutide 0.25 to 2.4 mg weekly, tirzepatide 2.5 to 15 mg weekly, retatrutide 2 to 12 mg weekly, BPC-157 250 to 500 mcg once or twice daily, TB-500 2 to 2.5 mg once or twice weekly, GHK-Cu 1 to 2 mg daily, and MOTS-c 5 to 10 mg two to three times weekly.
Common research doses for the seven most-searched peptides, with the evidence behind each one.

How to Read This Peptide Dosage Chart

Each row sums up the dosing section of a full guide on this site. Dose is the amount given each time, and an arrow (β†’) means the dose starts low and steps up over several weeks. How often is the usual schedule. Route is how it is given: SubQ is a small shot under the skin, and IM is a shot into a muscle.

Evidence tells you where each number comes from. A dose from an FDA label and a dose passed around online look the same in a table, so check this column before you compare two rows.

FDA label
The dose printed on an approved US drug label, such as Wegovy, Zepbound, or Vyleesi. It is the strongest evidence here, and it applies to that exact product and use.
Clinical trials
Doses tested in published human studies. They apply to the people and conditions those studies tested.
Clinic or compounding practice
Amounts that clinics and compounding pharmacies commonly use. No controlled trial has tested them.
Community
Amounts people in research communities report using. No human trial has set these doses, and nobody has shown they are safe.
Animal only
Only animal studies exist. Animal doses do not convert into a safe human dose.

Research peptides are not the same as prescription drugs

A research vial labeled semaglutide or tirzepatide is not proven to match Wegovy or Zepbound, and label doses apply only to the approved product. Talk to a licensed clinician before using any compound on this page.

Weight Loss and Metabolic Peptide Doses

GLP-1 drugs and related compounds start low and step up every four weeks so the stomach can adjust. Most are once-weekly shots. AOD-9604, 5-Amino-1MQ, and SLU-PP-332 rely on community reports because no human trial has set their doses.

Dose

0.25 mg β†’ 2.4 mg

How often

Once weekly, up every 4 weeks

Route

SubQ

Evidence

FDA label (Wegovy)

Dose

2.5 mg β†’ 15 mg

How often

Once weekly, up 2.5 mg every 4+ weeks

Route

SubQ

Evidence

FDA label (Zepbound)

Dose

2 mg β†’ 12 mg

How often

Once weekly, up every 4 weeks

Route

SubQ

Evidence

Clinical trials (Phase 3)

Dose

0.25 mg β†’ 2.4 mg

How often

Once weekly, 16-week ramp

Route

SubQ

Evidence

Clinical trials (Phase 3)

Dose

0.6–4.8 mg (trial arms)

How often

Once weekly

Route

SubQ

Evidence

Clinical trials (Phase 2/3)

Dose

0.25–0.5 mg

How often

Once daily, morning

Route

Oral tablet

Evidence

Clinical trials

Peptide

AOD-9604

Dose

300–500 mcg

How often

Once daily

Route

SubQ

Evidence

Community

Dose

50–100 mg oral; 2.5–5 mg SubQ

How often

Once daily

Route

Oral / SubQ

Evidence

Community

Peptide

Lipo-C

Dose

0.5–1 mL

How often

1–2x weekly

Route

SubQ / IM

Evidence

Compounding practice

Peptide

SLU-PP-332

Dose

25–50 mg

How often

Once daily

Route

Oral tablet

Evidence

Community (mouse data only)

Healing and Recovery Peptide Doses

Repair peptides have strong animal data but almost no human dosing trials. Most amounts below are the ones research communities share most often. Treat them as examples, since none has been proven in people. ARA-290 is the exception, with doses from human trials.

Peptide

BPC-157

Dose

250–500 mcg

How often

1–2x daily

Route

SubQ / oral

Evidence

Community

Peptide

TB-500

Dose

2–2.5 mg

How often

2x weekly, then 1x weekly

Route

SubQ

Evidence

Community

Peptide

GHK-Cu

Dose

1–2 mg

How often

Daily or 5 days a week

Route

SubQ / topical

Evidence

Community

Peptide

KPV

Dose

200–500 mcg

How often

Once daily

Route

SubQ / oral

Evidence

Community

Peptide

Cartalax

Dose

2–5 mg

How often

Once daily, about 12 weeks

Route

SubQ

Evidence

Community

Peptide

ARA-290

Dose

1–4 mg (up to 8 mg)

How often

Once daily, about 4 weeks

Route

SubQ

Evidence

Clinical trials

Growth Hormone Peptide Doses

These peptides signal the pituitary gland to release more growth hormone. Short-acting ones are taken daily, often before bed. CJC-1295 with DAC lasts about a week, so it is taken weekly.

Peptide

Ipamorelin

Dose

100–300 mcg a day

How often

Once daily or split in 2

Route

SubQ

Evidence

Community

Dose

100–200 mcg

How often

Once daily

Route

SubQ

Evidence

Community

Dose

1–2 mg

How often

Once weekly

Route

SubQ

Evidence

Community

Peptide

Sermorelin

Dose

200–300 mcg (100–500 range)

How often

Nightly

Route

SubQ

Evidence

Former FDA label

Dose

1.28–2 mg

How often

Once daily

Route

SubQ

Evidence

FDA label (Egrifta)

Peptide

GHRP-6

Dose

100–300 mcg

How often

3x daily, empty stomach

Route

SubQ

Evidence

Community

Peptide

IGF-1 LR3

Dose

20–40 mcg (up to 100)

How often

Once daily

Route

SubQ / IM

Evidence

Community

Brain, Mood and Sleep Peptide Doses

Several of these come from Russian medicine, where they are sold as nasal sprays. Nasal and injected doses are not the same, so compare doses within one route only.

Peptide

Selank

Dose

250–500 mcg SubQ; 600–2,700 mcg nasal

How often

Once daily (nasal: 2–3x)

Route

SubQ / nasal

Evidence

Community (SubQ); Russian clinical (nasal)

Peptide

Semax

Dose

0.6–1.5 mg a day

How often

Split into 2 doses

Route

Nasal (SubQ less common)

Evidence

Russian clinical

Peptide

Adamax

Dose

300–1,000 mcg

How often

Once daily

Route

SubQ / nasal

Evidence

Community (no direct studies)

Peptide

DSIP

Dose

100–300 mcg

How often

Evening

Route

SubQ

Evidence

Community

Peptide

Pinealon

Dose

1–2 mg

How often

Once daily, 10–20 days

Route

SubQ / oral

Evidence

Community

Dose

5–30 mL a day (clinical liquid)

How often

Daily courses of 10–21 days

Route

IV / IM

Evidence

Clinical trials

Anti-Aging, Skin and Energy Peptide Doses

This group mixes approved drugs, supplements, and compounds with only animal data. Check the Evidence column before comparing one row to another.

Peptide

NAD+

Dose

50–100 mg SubQ; 250–500 mg IV

How often

2–3x weekly (SubQ)

Route

SubQ / IV

Evidence

Clinic practice

Peptide

MOTS-c

Dose

5–10 mg

How often

2–3x weekly, 4–8 weeks

Route

SubQ

Evidence

Community (animal data)

Peptide

SS-31

Dose

40 mg

How often

Once daily

Route

SubQ

Evidence

FDA label (Barth syndrome only)

Peptide

Epitalon

Dose

5–10 mg

How often

Daily for 10–20 days, 2–3x a year

Route

SubQ

Evidence

Russian studies; community

Peptide

Humanin

Dose

No set human dose

How often

Varies

Route

SubQ

Evidence

Animal only

Peptide

FOXO4-DRI

Dose

250–500 mcg

How often

Once daily, 16 weeks

Route

SubQ

Evidence

Community (animal data only)

Dose

250–1,000 mg

How often

Daily

Route

Oral (IV in clinics)

Evidence

Clinical trials

Dose

250–1,000 mcg

How often

Daily to load, then 1–2x weekly

Route

SubQ

Evidence

Community

Dose

5–20 mg

How often

Daily, often split

Route

Oral

Evidence

Community

Immune Peptide Doses

Thymosin Alpha-1 has the clearest dosing here because it is an approved drug in many countries outside the US. The other two rely on community use.

Dose

1.6 mg

How often

2x weekly

Route

SubQ

Evidence

Approved outside the US

Peptide

VIP

Dose

50–200 mcg

How often

1–2x daily

Route

SubQ (nasal in clinics)

Evidence

Community

Peptide

LL-37

Dose

100–250 mcg (up to 500)

How often

Once daily, 5 days a week

Route

SubQ

Evidence

Community (trials were topical)

Sexual Health and Hormone Peptide Doses

PT-141 has a US label with clear limits. Kisspeptin and oxytocin doses depend heavily on the form and route, so read the full guide before comparing numbers.

Dose

1.75 mg

How often

As needed; max 1 a day, 8 a month

Route

SubQ

Evidence

FDA label (Vyleesi)

Peptide

Kisspeptin

Dose

50–200 mcg (kisspeptin-10)

How often

Once daily

Route

SubQ

Evidence

Community

Peptide

Oxytocin

Dose

24–48 IU a day

How often

Split 1–2x daily

Route

Nasal

Evidence

Clinical trials

Peptide Stack and Blend Doses

A blend dose is the total amount drawn from a mixed vial, so each compound gets a share of it. Only CagriSema has been tested as a combination in trials.

Dose

0.5–2 mg blend (250–1,000 mcg each)

How often

Daily

Route

SubQ

Evidence

Community

Dose

About 2.3 mg blend (10 units)

How often

Daily

Route

SubQ

Evidence

Community

Dose

2–6 mg blend

How often

Daily

Route

SubQ

Evidence

Community

Dose

100–300 mcg each

How often

Once daily, before bed

Route

SubQ

Evidence

Community

Dose

167–667 mcg each (5/5 vial)

How often

Once daily

Route

SubQ

Evidence

Community

Dose

0.25 mg β†’ 2.4 mg of each

How often

Once weekly

Route

SubQ

Evidence

Clinical trials (Phase 3)

Dose

Tirzepatide 2.5 β†’ 15 mg + cagrilintide 0.25 β†’ 2.4 mg

How often

Once weekly, staggered start

Route

SubQ

Evidence

Community

Dose

5:1 blend, starting at 2 mg + 0.4 mg

How often

Once weekly

Route

SubQ

Evidence

Community

Dose

Retatrutide weekly ramp + MOTS-c 5 mg

How often

Weekly + 2–3x weekly

Route

SubQ

Evidence

Community

Dose

Retatrutide 2 β†’ 12 mg + 200 mcg CJC/Ipa

How often

Weekly + nightly

Route

SubQ

Evidence

Community

Dose

Semax 300–800 mcg + Selank 250–500 mcg

How often

Once daily

Route

SubQ / nasal

Evidence

Community

How to Turn a Peptide Dose Into Syringe Units

Most peptides come as a dry powder. You add bacteriostatic (BAC) water, then draw the dose with a U-100 insulin syringe, where 100 units equals 1 mL. The same dose can be 5 units or 10 units depending on how much water went into the vial.

  1. 01

    Find the concentration

    Divide the vial amount by the water you added. A 10 mg vial with 2 mL of water holds 5 mg (5,000 mcg) per mL.

  2. 02

    Find the volume

    Divide your dose by the concentration. 250 mcg Γ· 5,000 mcg per mL = 0.05 mL.

  3. 03

    Convert to units

    Multiply the volume by 100. 0.05 mL Γ— 100 = 5 units on a U-100 syringe.

Peptide syringe units chart for U-100 syringes: 100 mcg is 4, 2, or 3 units; 250 mcg is 10, 5, or 7.5 units; 500 mcg is 20, 10, or 15 units; 1 mg is 40, 20, or 30 units; and 2 mg is 80, 40, or 60 units for a 5 mg vial with 2 mL, a 10 mg vial with 2 mL, and a 10 mg vial with 3 mL.
Units on a U-100 syringe for common doses and three common vial setups.

Syringe units for common doses (U-100 syringe)

Dose

100 mcg

5 mg vial + 2 mL

4 units

10 mg vial + 2 mL

2 units

10 mg vial + 3 mL

3 units

Dose

250 mcg

5 mg vial + 2 mL

10 units

10 mg vial + 2 mL

5 units

10 mg vial + 3 mL

7.5 units

Dose

500 mcg

5 mg vial + 2 mL

20 units

10 mg vial + 2 mL

10 units

10 mg vial + 3 mL

15 units

Dose

1 mg

5 mg vial + 2 mL

40 units

10 mg vial + 2 mL

20 units

10 mg vial + 3 mL

30 units

Dose

2 mg

5 mg vial + 2 mL

80 units

10 mg vial + 2 mL

40 units

10 mg vial + 3 mL

60 units

1 mg = 1,000 mcg. Concentrations: 5 mg + 2 mL = 2,500 mcg/mL; 10 mg + 2 mL = 5,000 mcg/mL; 10 mg + 3 mL = about 3,333 mcg/mL.

For any other vial size or water amount, use the free PepPal Reconstitution Calculator. Each protocol guide also has its own reconstitution table.

Peptide Supplies Needed

Measuring the doses on this chart takes a research vial, U-100 insulin syringes, and alcohol swabs. Check each supplier's testing records and current prices before you buy. Each protocol guide also links the matching product for that compound.

Recommended Supplies

Use discount code PEPPAL at Peptide Partners checkout. See why we love Peptide Partners.

Disclosure: supply links may earn PDP a commission at no cost to you.

Affiliate disclosure: PDP may earn a commission from eligible links at no added cost to you. Prices, stock, and testing records can change.

Companion Supplies & Routine Support

Why Peptide Dosage Charts Disagree

Dosage charts online often list different numbers for the same peptide. These are the usual reasons.

  • Most research peptides have no tested human dose. Charts copy community numbers from each other, and the numbers drift as they get copied. Rows here built on those numbers say "Community" in the Evidence column.
  • Nasal, oral, and injected doses of the same peptide can differ by 10 times or more, and some charts mix them. Each row here names its route, and the full guides keep each route separate.
  • A chart that lists "10 units" only works for the vial and water amount it assumed. Convert from mcg or mg yourself instead of copying someone else's units.
  • Some charts blend prescription drugs with research products. A drug label dose applies only to that product, and a research powder with the same name is a different product.

Peptide Dosage Chart FAQ

Q1: What is a normal peptide dose?

There is no single normal dose. Peptide doses range from about 20 mcg (IGF-1 LR3) to 2 mg or more (TB-500, tirzepatide), and some are given daily while others are weekly. Find the peptide in the chart above, then open its full guide for the schedule.

Q2: How many units is 250 mcg?

It depends on the vial. With a 10 mg vial and 2 mL of water, 250 mcg is 5 units on a U-100 syringe. With a 5 mg vial and 2 mL, it is 10 units. With a 10 mg vial and 3 mL, it is 7.5 units. See the syringe units chart.

Q3: What is the difference between mcg and mg?

1 mg (milligram) equals 1,000 mcg (micrograms). Many peptides are dosed in mcg, like BPC-157 at 250 mcg. GLP-1 drugs are dosed in mg, like semaglutide at 2.4 mg. Mixing up the two is a 1,000-times error, so check the unit every time.

Q4: Do you take peptides every day?

Some, not all. BPC-157, KPV, and most growth hormone peptides are usually daily. Semaglutide, tirzepatide, and retatrutide are once weekly. TB-500 and Thymosin Alpha-1 are about twice weekly. The How often column shows the usual schedule for each one.

Q5: Are peptide doses based on body weight?

Usually not. Most label and community doses are fixed amounts. A few exceptions use weight, such as Thymosin Alpha-1 for adults under 40 kg and many animal studies. Animal doses by weight do not convert into a safe human dose.

Q6: Why do GLP-1 doses go up every 4 weeks?

Starting low and stepping up slowly gives the stomach time to adjust and lowers nausea. The Wegovy and Zepbound labels and the retatrutide Phase 3 trials all use four-week steps. A label allows staying at a lower step longer if side effects are hard to tolerate.

Q7: Where do the doses on this chart come from?

Each row summarizes the dosing section of the linked guide on this site. Those guides cite FDA labels, published trials, and clearly labeled community sources. The Evidence column shows which kind of source each row is based on.

Q8: Is this chart medical advice?

No. This is an educational reference. Most compounds here are not FDA-approved, and community doses have not been proven safe. Talk to a licensed clinician before using any peptide.

Sources

  1. 1. U.S. Food and Drug Administration. Wegovy (semaglutide) injection and tablets - Prescribing Information (June 2026). FDA (2026)
  2. 2. U.S. Food and Drug Administration Zepbound (tirzepatide) injection β€” Prescribing Information (revised August 2026). Eli Lilly / FDA-approved prescribing information (2026)
  3. 3. Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism (2025)
  4. 4. Garvey WT, BlΓΌher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine (2025)
  5. 5. Le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology (2024)
  6. 6. U.S. Food and Drug Administration Egrifta SV (tesamorelin) prescribing information. FDA (2024)
  7. 7. U.S. Food and Drug Administration. FORZINITY (elamipretide) injection β€” Highlights of Prescribing Information. accessdata.fda.gov (2025)
  8. 8. Bremelanotide (subcutaneous route) β€” Description and Dosing. Mayo Clinic Drugs & Supplements (2026)
  9. 9. Dominari A, et al. Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology (2020)
  10. 10. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. The Lancet (2008)
  11. 11. Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular Medicine (2012)
  12. 12. Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition (2015)
  13. 13. Sikich L, Kolevzon A, King BH, McDougle CJ, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. New England Journal of Medicine (2021)

Related Dosing Protocols

Educational use only

This chart is an educational research reference and is not medical advice. Most compounds listed are not FDA-approved, and community-reported doses have not been shown to be safe or effective in people. Consult a licensed healthcare provider before considering any peptide.

Need the full schedule?

Every row in this chart links to a full guide with the week-by-week schedule, reconstitution table, side effects, and sources.

Garret Grant

Written by Garret Grant

Founder & Lead Researcher Β· B.S. Civil Engineering, UCLA

Last updated: November 2026

Human-researched and AI-assisted with full editorial review. I verify sources, protocol interpretation, and final judgments personally. See methodology.

Share this page

See our research first on Google

Add us as a preferred source for Top Stories.

Add as preferred source